Takeda And Asuka Agree To Make ARB Blopress Generic
This article was originally published in PharmAsia News
Executive Summary
In Japan, Takeda and Asuka have reached an agreement whereby the latter may sell a generic form of Takeda’s ARB Blopress (candesartan) with the same ingredients, additives, and productions methods as the forerunner drug, the companies announced on May 16.